Artelo Biosciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

LEASE

LEASE

3 Months Ended

Mar. 31, 2026

NOTE 9 – LEASE

On May 12, 2021, the Company entered into a lease arrangement for office space in the U.S. On March 6, 2024, the Company entered into an amended agreement with the landlord to extend the lease commencing in September 2024, and effective until August 2027.

The following summarizes right-of use asset and lease information about the Company’s operating leases as of March 31, 2026:

	Three Months Ended
	March 31,
	2026			2025

Lease cost
Operating lease cost	$	9		$	8

Other information
Cash paid for operating cash flows from operating leases	$	10		$	8

Weighted-average remaining lease term — operating leases (year)		1.33			2.33
Weighted-average discount rate — operating leases		7.50	%		7.50	%

Future minimum lease payments under the operating lease liability have non-cancellable lease payments at March 31, 2026, as follows:

	Total
Year Ended December 31,
2026	$	33
2027		30
2028		-
2029		-
Thereafter		-
		63
Less: Imputed interest		(4	)
Operating lease liabilities		59

Operating lease liability - current		41
Operating lease liability - non-current	$	18